Steven A Blackwell, Melissa A Montgomery, Dave K Baugh, Gary M Ciborowski, Gerald F Riley
{"title":"Applying the 2003 Beers update to elderly Medicare enrollees in the Part D program.","authors":"Steven A Blackwell, Melissa A Montgomery, Dave K Baugh, Gary M Ciborowski, Gerald F Riley","doi":"10.5600/mmrr.002.02.a01","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Inappropriate prescribing of certain medications known as Beers drugs may be harmful to the elderly, because the potential risk for an adverse outcome outweighs the potential benefit.</p><p><strong>Objectives: </strong>(1) To assess Beers drug use in dual enrollees compared to non-duals; (2) to explore the association between dual enrollment status and Beers use, controlling for the effects of age, gender, race/ethnicity, census region, and health status; (3) to assess which medication therapeutic category had the highest Beers use.</p><p><strong>Design: </strong>Cross sectional retrospective review of 2007 Centers for Medicare & Medicaid Service Part D data. Potentially inappropriate medication use was assessed, independent of diagnosis, using the 2003 update by Fick et al.</p><p><strong>Findings: </strong>The likelihood of Beers drug use among duals approximates that of non-duals (OR 1.023, 95% CI 1.020-1.026). Characteristics associated with the receipt of a Beers medication include Hispanic origin, younger age, female gender, poor health status, and residence outside of the U.S.' Northeast region. Genitourinary products had the highest Beers use within medication therapeutic categories among both dual and non-dual enrollees (21.1% and 19.9%, respectively).</p><p><strong>Conclusions: </strong>Part D data can be successfully used to monitor Beers drug use. With adjustments for several important and easily measured demographic, health, and prescription drug use covariates, Beers drug use appears to be as common among non-dual enrollees as it is among dual enrollees in the Part D program. New Part D drug utilization policies that apply to all beneficiaries may need to be enacted to reduce Beers drug use.</p>","PeriodicalId":89601,"journal":{"name":"Medicare & medicaid research review","volume":"2 2","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2012-05-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4006423/pdf/mmrr2012-002-02-a01.pdf","citationCount":"5","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Medicare & medicaid research review","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5600/mmrr.002.02.a01","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2012/1/1 0:00:00","PubModel":"eCollection","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 5
Abstract
Background: Inappropriate prescribing of certain medications known as Beers drugs may be harmful to the elderly, because the potential risk for an adverse outcome outweighs the potential benefit.
Objectives: (1) To assess Beers drug use in dual enrollees compared to non-duals; (2) to explore the association between dual enrollment status and Beers use, controlling for the effects of age, gender, race/ethnicity, census region, and health status; (3) to assess which medication therapeutic category had the highest Beers use.
Design: Cross sectional retrospective review of 2007 Centers for Medicare & Medicaid Service Part D data. Potentially inappropriate medication use was assessed, independent of diagnosis, using the 2003 update by Fick et al.
Findings: The likelihood of Beers drug use among duals approximates that of non-duals (OR 1.023, 95% CI 1.020-1.026). Characteristics associated with the receipt of a Beers medication include Hispanic origin, younger age, female gender, poor health status, and residence outside of the U.S.' Northeast region. Genitourinary products had the highest Beers use within medication therapeutic categories among both dual and non-dual enrollees (21.1% and 19.9%, respectively).
Conclusions: Part D data can be successfully used to monitor Beers drug use. With adjustments for several important and easily measured demographic, health, and prescription drug use covariates, Beers drug use appears to be as common among non-dual enrollees as it is among dual enrollees in the Part D program. New Part D drug utilization policies that apply to all beneficiaries may need to be enacted to reduce Beers drug use.
背景:某些被称为比尔斯的药物的不当处方可能对老年人有害,因为潜在的不良后果风险大于潜在的益处。目的:(1)评估双组受试者与非双组受试者的比尔斯药物使用情况;(2)在控制年龄、性别、种族/民族、人口普查地区和健康状况的影响下,探讨双入学状态与啤酒使用的关系;(3)评估哪种药物治疗类别的比尔斯使用率最高。设计:对2007年医疗保险和医疗补助服务中心D部分数据进行横断面回顾性评价。使用菲克等人2003年更新的独立于诊断的潜在不适当用药进行评估。研究结果:双胎患者使用比尔斯药物的可能性与非双胎患者相近(OR 1.023, 95% CI 1.020-1.026)。与接受比尔斯药物相关的特征包括西班牙裔、年轻、女性、健康状况不佳以及居住在美国以外。”东北地区。在双重和非双重受试者中,泌尿生殖系统产品在药物治疗类别中的使用率最高(分别为21.1%和19.9%)。结论:D部分数据可以成功地用于监测比尔斯的用药情况。在调整了几个重要且容易测量的人口统计、健康和处方药使用协变量后,比尔斯的药物使用在非双重参与者中似乎和在D部分项目的双重参与者中一样普遍。可能需要制定适用于所有受益人的新的D部分药物使用政策,以减少比尔斯的药物使用。